Though more healthcare providers are using chatbots—or conversational AI—to connect with patients, the technology needs to improve in certain areas to earn the trust of its users and achieve widespread adoption, according to recent survey by UserTesting.
RFPi, a Greenville, North Carolina-based medical imaging company, announced that its iCertainty blood flow and perfusion imaging solution has received FDA clearance.
The FDA is fast-tracking efforts to produce an over-the-counter version of naloxone, a life-saving drug which can reverse an opioid overdose. Current FDA-approved versions of naloxone require a prescription, creating a barrier of use for some.
Women implanted with cardiac implantable electronic devices (CIEDs) like pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy technologies are more likely to experience acute CIED complications than men who undergo the same procedures, according to work published Jan. 16 in the Journal of the American Heart Association.
Although online portals allow some patients to easily access their radiology reports, new research published Jan. 8 in the American Journal of Roentgenology found that lumbar spine MRI reports in particular are written at a reading level too advanced for the average patient to comprehend.
Invasive lobular, low-grade and HER-2-negative breast cancers are more detectable with digital breast tomosynthesis (DBT) than full-field digital mammography (FFDM) when imaging patients with dense breasts, according to a new study published in the Korean Journal of Radiology.
CVS Health and Walmart have reached a new, multiyear deal to continue their pharmacy business relationship. CVS announced the agreement Jan. 18, three days after the companies stated they would no longer be in the same network for filling prescription drugs after a pricing dispute.
Healthcare, including imaging, is one of 13 industries that will soon be “revolutionized" by artificial intelligence (AI) and machine learning (ML) technologies, according to a new report published in Forbes.
Following a series of valsartan recalls over carcinogenic impurities, at least three sellers of the popular blood-pressure medication hiked their prices, the Wall Street Journal reported.
